PRFX.US PRF Technologies Ltd.

Healthcare Biotechnology USA Stocks
0.6610 USD
Close of Nov 18, 2026
0.6410 7.95
Market cap
USD 2.31M
P/E
-
P/B
0.15x
ROE
-35.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is PRFX.US undervalued?

Graham number

The Graham number of PRF Technologies Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PRF Technologies Ltd. fundamental analysis

No fundamental analysis for PRF Technologies Ltd. yet.

PRF Technologies Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PRF Technologies Ltd.

PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd. and chang…

Full company profile